ea0011p918 | Thyroid | ECE2006
Salvi M
, Vannucchi GM
, Campi I
, Guastella C
, Sbrozzi F
, Simonetta S
, Rossi S
, Bonara P
, Avignone S
, Ratiglia R
We are conducting an open study on the treatment of GravesÂ’ disease (GD) and thyroid-associated ophthalmopathy (TAO) with the monoclonal antibody to CD-20, rituximab (RTX) (MabThera, Hoffman-Roche, Basel). RTX induces depletion of B cells and GD is typically a B cell dependent autoimmune disease. We present preliminary results on 7 patients with GD and TAO at different clinical stages: 3 women with newly diagnosed GD and initial TAO; 1 woman with GD and moderate-severe TA...